A prior trial tested this vaccine (IDH1 R132H peptide vaccine) for gliomas with this IDH1 mutation. The current trial is testing vaccine alone versus avelumab (PD-L1 inhibitor) alone versus combined vaccine + avelumab.
It is recruiting first recurrent gliomas of grade 2-4 with the IDH1 R132H mutation.
Open in Heidelberg and Mannheim Germany, and will also be open at several other centres in Germany.
https://clinicaltrials.gov/ct2/show/NCT03893903
Showing posts with label avelumab. Show all posts
Showing posts with label avelumab. Show all posts
Tuesday, 2 April 2019
Subscribe to:
Posts (Atom)